Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AVMXY NYSE:IKT OTCMKTS:OSIR NYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVMXYAVITA MED LTD/S$7.89$7.89$1.06▼$8.58$651.87M1.28183,275 shsN/AIKTInhibikase Therapeutics$1.84-0.3%$1.90$1.12▼$4.20$136.12M0.92280,122 shs10,424 shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/APRMEPrime Medicine$5.09+23.2%$2.24$1.11▼$5.95$678.67M2.331.81 million shs2.34 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVMXYAVITA MED LTD/S0.00%0.00%0.00%0.00%0.00%IKTInhibikase Therapeutics0.00%-0.54%+10.84%-2.65%+22.67%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%PRMEPrime Medicine0.00%-5.06%+99.52%+197.12%-22.15%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/AN/AN/AN/AIKTInhibikase Therapeutics1.2494 of 5 stars3.31.00.00.00.00.00.6OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APRMEPrime Medicine3.8388 of 5 stars4.41.00.00.03.15.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVMXYAVITA MED LTD/S 0.00N/AN/AN/AIKTInhibikase Therapeutics 2.50Moderate Buy$6.50254.22% UpsideOSIROsiris Therapeutics 0.00N/AN/AN/APRMEPrime Medicine 2.75Moderate Buy$9.2581.84% UpsideCurrent Analyst Ratings BreakdownLatest AVMXY, OSIR, PRME, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVMXYAVITA MED LTD/S$5.51M118.31N/AN/A$0.26 per share30.35IKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/APRMEPrime Medicine$3.85M177.89N/AN/A$1.37 per share3.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVMXYAVITA MED LTD/S-$24.75M-$0.39N/A∞N/AN/AN/AN/AN/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AOSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVMXYAVITA MED LTD/SN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/APRMEPrime Medicine$1.4528.43%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVMXYAVITA MED LTD/SN/A5.505.33IKTInhibikase TherapeuticsN/A0.850.85OSIROsiris TherapeuticsN/AN/AN/APRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVMXYAVITA MED LTD/S0.01%IKTInhibikase Therapeutics3.81%OSIROsiris Therapeutics0.28%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipAVMXYAVITA MED LTD/SN/AIKTInhibikase Therapeutics7.30%OSIROsiris Therapeutics43.40%PRMEPrime Medicine22.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVMXYAVITA MED LTD/S5582.62 millionN/ANot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableOSIROsiris Therapeutics34234.53 millionN/ANot OptionablePRMEPrime Medicine234134.50 million100.38 millionOptionableAVMXY, OSIR, PRME, and IKT HeadlinesRecent News About These CompaniesWhat is Wedbush's Estimate for Prime Medicine Q2 Earnings?July 20 at 2:07 AM | americanbankingnews.comPrime Medicine (NYSE:PRME) Stock Price Down 6.6% - Time to Sell?July 18 at 6:15 PM | marketbeat.comWedbush Has Positive Forecast for Prime Medicine Q2 EarningsJuly 18 at 9:34 AM | marketbeat.comPrime Medicine (NYSE:PRME) Receives Outperform Rating from WedbushJuly 18 at 2:18 AM | americanbankingnews.comPrime Medicine's (PRME) "Outperform" Rating Reiterated at WedbushJuly 17, 2025 | marketbeat.comPrime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic AdvancementsJuly 17, 2025 | tipranks.comPrime Medicine Shares Drop After New Funding, Equity InvestmentJuly 16, 2025 | marketwatch.comPrime Medicine (NYSE:PRME) Sees Large Volume Increase - Here's WhyJuly 16, 2025 | marketbeat.comCystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing TherapyJuly 16, 2025 | businesswire.comPrime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic FibrosisJuly 16, 2025 | globenewswire.comPrime Medicine (NYSE:PRME) Trading 7.4% Higher - Should You Buy?July 14, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Down 11.8% - Should You Sell?July 11, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Sees Strong Trading Volume - What's Next?July 9, 2025 | marketbeat.comPrime Medicine: Pressing Forward With Lead Liver Targeting IndicationsJuly 7, 2025 | seekingalpha.comPrime Medicine stock soars amid gene editing sector momentumJuly 7, 2025 | finance.yahoo.comPrime Medicine, Inc.: Buy Rating Driven by Strategic Positioning and Market MomentumJuly 7, 2025 | tipranks.comStock Traders Purchase High Volume of Prime Medicine Call Options (NYSE:PRME)July 7, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Gap Up - What's Next?July 7, 2025 | marketbeat.comPrime Medicine Focuses on Genetic Liver Diseases, Partnered Programs After Positive CGD DataJuly 6, 2025 | msn.comSumitomo Mitsui Trust Group Inc. Sells 164,157 Shares of Prime Medicine, Inc. (NYSE:PRME)July 4, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by AnalystsJune 29, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVMXY, OSIR, PRME, and IKT Company DescriptionsAVITA MED LTD/S OTCMKTS:AVMXYAvita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products for the treatment of burns, chronic wounds, and aesthetics indications. The company's patented and proprietary collection and application technology provides treatment solutions derived from a patient's own skin. Its lead product, RECELL System, is used in the treatment of various skin defects, such as burns and plastic reconstructive procedures. The company also offers ReGenerCell for chronic wounds and ReNovaCell for the restoration of pigmentation. Avita Medical Limited is based in Valencia, California.Inhibikase Therapeutics NYSE:IKT$1.84 -0.01 (-0.27%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Prime Medicine NYSE:PRME$5.09 +0.96 (+23.17%) As of 10:21 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
